About cangrelor
Intravenous P2Y12 platelet inhibitor
Used for
- Reduces clot-related heart attack complications during percutaneous coronary intervention (PCI) in adults unable to take oral P2Y12 inhibitors.
- May be used when oral treatment is unsuitable or not possible.
Usual adult dose
PCI: 30 micrograms/kg intravenously as a bolus, followed immediately by 4 micrograms/kg/minute infusion for at least two hours or the procedure duration, whichever is longer.
Common side effects
- Bleeding
- Shortness of breath
- Low blood pressure
- Allergic reactions
Important warnings
- Bleeding is the main risk; serious or fatal bleeding can occur.
- Avoid with active significant bleeding or a history of stroke or transient ischemic attack.
- Stop the infusion before surgery when clinically appropriate; platelet function usually recovers within about an hour.
- Use only in a monitored clinical setting.
Pregnancy
Human pregnancy data are limited. Use only if the potential benefit justifies possible fetal risk.
Breastfeeding
It is unknown whether cangrelor enters breast milk. Breastfeeding decisions should consider treatment need and potential infant risk.
Interactions
- Clopidogrel or prasugrel given during infusion may have reduced antiplatelet effect; administer after infusion stops.
- Ticagrelor can be given during or immediately after infusion.
- Other medicines that increase bleeding risk may raise bleeding risk further.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.